TY - JOUR
T1 - Impact of coronavirus disease 2019 on medical practice in endocrine and metabolic diseases in Japan
T2 - a nationwide surveillance study conducted by the Japan Endocrine Society
AU - Manaka, Katsunori
AU - Kato, Sayaka
AU - Sakamoto, Ryuichi
AU - Yamakage, Hajime
AU - Uema, Tsugumi
AU - Kawai, Shiori
AU - Shibata, Megumi
AU - Hiratsuka, Izumi
AU - Nakachi, Sawako
AU - Onoue, Takeshi
AU - Tsuchiya, Takefumi
AU - Fukui, Michiaki
AU - Hashimoto, Koshi
AU - Suzuki, Atsushi
AU - Makita, Noriko
AU - Ogawa, Yoshihiro
AU - Arima, Hiroshi
AU - Satoh-Asahara, Noriko
AU - Masuzaki, Hiroaki
N1 - Publisher Copyright:
© The Japan Endocrine Society.
PY - 2024
Y1 - 2024
N2 - We investigated the impact of the Coronavirus disease 2019 (COVID-19) pandemic on the management of endocrine and metabolic disorders in Japan. We conducted a cross-sectional nationwide questionnaire survey targeting board-certified endocrinologists under the auspices of the Japan Endocrine Society. The questionnaire consisted of multiple-choice questions and open-ended responses. Out of approximately 2,700 specialists, 528 (19.5%) opted to participate, suggesting a high level of interest in COVID-19 management among endocrinologists. The study found that almost half of participants had encountered cases of endocrine and metabolic disorders following COVID-19 infection or vaccination. Conditions related to thyroid diseases, glucose metabolism disorders/diabetes, and hypothalamic-pituitary disorders were particularly prevalent. Diabetes and obesity were identified as having high rates of severe cases or fatalities due to COVID-19. The study also highlighted challenges in routine diagnosis and treatment, emphasizing the potential benefits of combining remote consultations with in-person visits to optimize the frequency of examinations and check-ups during infectious disease outbreak which disrupts access to healthcare providers. The insights obtained from this survey are expected to contribute to ensuring appropriate healthcare provision for patients with endocrine and metabolic disorders by using flexible consultation formats, particularly even in the conditions where medical access may be limited due to future outbreaks of emerging or re-emerging infectious diseases.
AB - We investigated the impact of the Coronavirus disease 2019 (COVID-19) pandemic on the management of endocrine and metabolic disorders in Japan. We conducted a cross-sectional nationwide questionnaire survey targeting board-certified endocrinologists under the auspices of the Japan Endocrine Society. The questionnaire consisted of multiple-choice questions and open-ended responses. Out of approximately 2,700 specialists, 528 (19.5%) opted to participate, suggesting a high level of interest in COVID-19 management among endocrinologists. The study found that almost half of participants had encountered cases of endocrine and metabolic disorders following COVID-19 infection or vaccination. Conditions related to thyroid diseases, glucose metabolism disorders/diabetes, and hypothalamic-pituitary disorders were particularly prevalent. Diabetes and obesity were identified as having high rates of severe cases or fatalities due to COVID-19. The study also highlighted challenges in routine diagnosis and treatment, emphasizing the potential benefits of combining remote consultations with in-person visits to optimize the frequency of examinations and check-ups during infectious disease outbreak which disrupts access to healthcare providers. The insights obtained from this survey are expected to contribute to ensuring appropriate healthcare provision for patients with endocrine and metabolic disorders by using flexible consultation formats, particularly even in the conditions where medical access may be limited due to future outbreaks of emerging or re-emerging infectious diseases.
KW - Coronavirus disease 2019 (COVID-19)
KW - Endocrine and metabolic diseases
KW - Pandemic
KW - Post COVID-19 condition (long COVID)
UR - http://www.scopus.com/inward/record.url?scp=85194112316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85194112316&partnerID=8YFLogxK
U2 - 10.1507/endocrj.EJ23-0671
DO - 10.1507/endocrj.EJ23-0671
M3 - Article
C2 - 38462511
AN - SCOPUS:85194112316
SN - 0918-8959
VL - 71
SP - 499
EP - 514
JO - Endocrine Journal
JF - Endocrine Journal
IS - 5
ER -